Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri scMRD Assay for AML. Learn More
X
publication

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?


Wei, A.H. et al.
Cancer Discovery (2019)
Abstract

In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and commonly mediated by heterogeneous mutations that activate downstream RAS-MAPK pathways. These findings and recent data from others indicate that emergence of multiple clones, each with distinct mechanisms of resistance, is a common finding at secondary failure of single-agent-targeted therapies for relapsed leukemias..



Authors

Wei, A.H., Roberts, A.W.



VIEW

publication
Phenotypic signatures of immune selection in HIV-1 reservoir cells
Weiwei Sun
Nature
publication
Mutated cells mediate distinct inflammatory responses in clonal hematopoiesis
J. Brett Heimlich
BioRxiv
publication
scTAM-seq enables targeted high-confidence analysis of DNA methylation in single cells
Bianchi A
Genome Biology (2022)
publication
Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
Troy T. Robinson
BioRxiv (2022)
REQUEST QUOTE